From new research to FDA nods, here are six key updates in the spine and orthopedic regenerative medicine space since Sept. 1.
1. Bone marrow aspirate injections didn't lead to significant changes for patients who had arthroscopic partial meniscectomy, according to a Sept. 15 study in The American Journal of Sports Medicine.
2. Cerapedics earned FDA approval to expand the use of its spinal fusion biologic, i-Factor P-15. Indications for the peptide enhanced bone graft now include single-level anterior cervical discectomy fusion with an allograft bone ring. It can also be used in conjunction with a PEEK titanium alloy or fusion device that has been cleared by the FDA for cervical spine use.
3. Zetagen Therapeutics' ZetaFuse has potential to treat degenerative disc disease in patients with late-stage cancer, according to a case study in the Journal of the American Academy of Orthopaedic Surgeons.
4. McAllen, Texas-based Altus Spine and Joint Pain Center partnered with Regenexx to provide noninvasive regenerative medicine services for orthopedic patients.
5. Medical technology company Enovis is partnering with Ossium Health to distribute viable bone matrix allografts.
6. Amphix Bio earned FDA breakthrough device designation for a bone regeneration drug-device combination.